Background: Leucine-rich repeats and immunoglobulin-like domains protein 1, also designated LIG1 or LRIG1, interacts with the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. LRIG1 is a single-pass, type I membrane protein with an ectodomain containing 15 leucine-rich repeats which is sometimes cleaved into N-terminal and C-terminal fragments. LRIG1 is produced in all human glioma cell lines and localizes to perinuclear compartments, cytoplasmic compartments and the cell surface. It acts as a negative feedback regulator of signaling through enhanced receptor ubiquitination and accelerated intracellular degradation. LRIG1 may function as a tumour suppressor since it downregulates the expression of EGF and the related proteins ErbB-2, ErbB-3 and ErbB-4, which all inhibit cancer cells from growth, migration and invasion.
Description: Rabbit polyclonal to LRIG2
Immunogen: KLH conjugated synthetic peptide derived from LRIG2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 143 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;
·Immunocytochemistry: 1/100-200;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
